Use of indole derivatives as chemiluminescence enhancers and kit containing the enhancers

Indole derivatives combined with phenothiazine compounds as enhancers in chemiluminescent reactions stabilize and maintain sensitivity, addressing the stability issues of existing enhancers, improving assays and immunoblotting experiments.

CN114755403BActive Publication Date: 2024-12-03DALIAN BOGLIN BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210218995.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-03-08
Publication Date
2024-12-03
Estimated Expiration
2042-03-08

AI Technical Summary

Technical Problem

Existing phenothiazine enhancers for chemiluminescence in ELISA and immunoblotting experiments provide high brightness but poor stability, necessitating new enhancer combinations that maintain sensitivity and stability without significant decay.

Method used

Combining indole derivatives with phenothiazine compounds as first and second enhancers, along with luminol or isoluminol as substrates, and incorporating stabilizers and moisturizers to enhance chemiluminescence stability and sensitivity.

Benefits of technology

The synergistic effect of phenothiazine and indole derivatives stabilizes luminescence while maintaining high sensitivity, ensuring prolonged luminescence time and improved adhesion to solid carriers, enhancing accuracy in enzyme-linked immunosorbent assays and immunoblotting experiments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114755403B_ABST
    Figure CN114755403B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of chemiluminescent reagents, and discloses the use of indole derivatives as chemiluminescent enhancers and a kit containing the enhancer. In the use, the indole derivative is used as a second enhancer in combination with a phenothiazine compound as a first enhancer; further, the phenothiazine compound is selected from one of 3-(10-phenothiazinyl) propane-1-sodium sulfonate, 10-(3-dimethylaminopropyl) phenothiazine and its derivatives; further, the indole derivative is selected from one or more of tryptophan, 5-hydroxytryptamine, auxin, or indole-3-acetic acid. The present invention uses a combination of phenothiazine compounds and indole derivatives to exert a synergistic effect, which not only improves the brightness of the luminescent reagent, but also prolongs the luminescence time due to the mutual transfer of electrons.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of chemiluminescent reagents and discloses the use of indole derivatives as chemiluminescent enhancers and a kit containing the enhancer. Background Art

[0002] The chemiluminescent reaction of luminol and peroxide compounds catalyzed by horseradish peroxidase (HRP) is widely used in the detection and analysis of antigens and antibodies, especially in enzyme-linked immunosorbent assay (ELISA) and immunoblotting experiments. Horseradish peroxidase is coupled to the antigen or antibody, and the amount of the antigen or antibody is indirectly analyzed by measuring the amount of HRP.

[0003] Luminol is a classic chemiluminescent reaction, and many compounds have been successfully used to enhance HRP-induced chemiluminescence, including: p-iodophenol, p-coumarin and other phenolic enhancers, in addition to phenolic enhancers, there are acetanilide and phenothiazines, among which phenothiazines are relatively newly discovered enhancers. Compared with other luminescence enhancers, phenothiazines have stronger luminescence intensity, especially when an enhancer such as imidazole or 4-morpholinylpyridine is added as a second enhancer, that is, a co-enhancer, the luminescence intensity and luminescence stability are stronger.

[0004] However, the existing phenothiazine enhancers and the reported second enhancers have a large increase in brightness but poor stability. Therefore, it is still necessary to develop new enhancer combinations based on the theory of new enhancers and second enhancers to improve the stability of chemiluminescence without reducing the sensitivity of chemiluminescence too much, and ensure that the luminescence intensity decays by less than 10% within two hours. Summary of the invention

[0005] In view of the above situation, the present invention discloses the use of indole derivatives as chemiluminescence enhancers and a kit containing the enhancer.

[0006] The technical solution of the present invention is as follows:

[0007] The invention discloses a use of an indole derivative as a chemiluminescence enhancer, wherein the indole derivative is used as a second enhancer in combination with a phenothiazine compound as a first enhancer.

[0008] Furthermore, in the above use, the phenothiazine compound is selected from one of 3-(10-phenothiazinyl)propane-1-sodium sulfonate, 10-(3-dimethylaminopropyl)phenothiazine and their derivatives.

[0009] Furthermore, in the above use, the indole derivative is selected from one or more of tryptophan, 5-hydroxytryptamine, auxin, or indole-3-acetic acid.

[0010] Furthermore, in the above use, the final concentration of the indole derivative in the chemiluminescent reagent is between 1-30 mM.

[0011] Furthermore, a chemiluminescent reagent includes a phenothiazine compound as a first enhancer; an indole derivative as a second enhancer; and luminol, isoluminol or a luminol-related derivative as a luminescent substrate.

[0012] Furthermore, a chemiluminescent kit comprises the above chemiluminescent reagent.

[0013] Furthermore, the above-mentioned chemiluminescent kit includes liquid A and liquid B.

[0014] The A solution includes a chemiluminescent reagent, a buffer A and a moisturizer;

[0015] The B solution includes a peroxidant, a stabilizer and a buffer B.

[0016] Furthermore, the above chemiluminescence kit,

[0017] The A liquid comprises:

[0018] 1) Luminescent substrate: selected from luminol, isoluminol or luminol-related derivatives;

[0019] 2) A first enhancer: one selected from sodium 3-(10-phenothiazinyl)propane-1-sulfonate, 10-(3-dimethylaminopropyl)phenothiazine and derivatives thereof;

[0020] 3) A second enhancer: one or more selected from tryptophan, 5-hydroxytryptamine, auxin, and indole-3-acetic acid;

[0021] 4) Buffer A: a buffer with a pH value between 8 and 9.5;

[0022] The B solution includes:

[0023] 1) Peroxidant: selected from one of hydrogen peroxide, urea hydrogen peroxide or perborate;

[0024] 2) Stabilizer: one selected from ethylenediaminetetraacetic acid, cyclohexaneethylenediaminetetraacetic acid, ethylene glycol tetraacetic acid, and diethyltriaminepentaacetic acid;

[0025] 3) Buffer B: pH value is within the range of 2-6, selected from one of acetic acid, benzoic acid, phosphoric acid and citric acid.

[0026] Furthermore, in the above chemiluminescence kit, the liquid A also includes: 5) a moisturizer: one or more selected from glycerol, hyaluronic acid, and propylene glycol.

[0027] Furthermore, the above chemiluminescence kit preferably comprises the following components:

[0028] It consists of two components, liquid A and liquid B. The two components are mixed before use. The mixing ratio is determined according to the final concentration and is not limited to a specific mixing ratio.

[0029] The A solution has the following components:

[0030] 1) Luminescent substrates, including luminol, isoluminol and luminol-related derivatives, dosage: between 0.5-10mM

[0031] 2) The first enhancer: a phenothiazine compound, one of 3-(10-phenothiazinyl) propane-1-sulfonate sodium, 10-(3-dimethylaminopropyl) phenothiazine and its derivatives, dosage: between 1-20 mM.

[0032] 3) Second enhancer: indole derivatives, mainly including Tryptophan , 5-hydroxytryptamine, auxin, and indole-3-acetic acid, one or more of which are mixed in an amount between 1-30 mM.

[0033] 4) Buffer A: mainly selected from common buffers in the buffer range of pH 8-9.5, including Tris-HCl, borate and the like, dosage: 10-200 mM.

[0034] 5) Moisturizers: including glycerin, hyaluronic acid, and propylene glycol, with the dosage ranging from 500-2000mM.

[0035] Wherein the B solution has the following components:

[0036] 1) Peroxidant, including one of hydrogen peroxide, urea hydrogen peroxide and perborate, with the dosage between 0.01mM and 10mM.

[0037] 2) Stabilizer, also a chelating agent, is one of ethylenediaminetetraacetic acid, cyclohexaneethylenediaminetetraacetic acid, ethylene glycol tetraacetic acid, and diethyltriaminepentaacetic acid, and the dosage is between 0.001mM-0.1mM.

[0038] 3) Buffer B, pH value is in the range of 2-6, selected from one of acetic acid, benzoic acid, phosphoric acid, and citric acid, and the dosage is between 10mM and 100mM.

[0039] Furthermore, the above chemiluminescent reagent or chemiluminescent kit is used in preparing a kit for immunoblotting experiment or enzyme-linked immunosorbent assay.

[0040] The present invention has the following beneficial effects:

[0041] In the prior art, the quantum yield of the luminescence reaction is low and the reaction speed is fast when luminol and peroxide compounds react alone. By adding an enhancer, the chemiluminescence oxidation is made faster, the brightness is higher and it is stable. According to the existing chemiluminescence principle, it can be called a "ping-pong" mechanism. The luminescence process is to activate horseradish peroxidase into an oxidative intermediate by hydrogen peroxide. The oxidative intermediate of the enzyme oxidizes the enhancer into its free radical product. This product will react reversibly with the luminol molecule, and finally, after multiple steps of basic reactions, luminol will generate an excited state of 3-aminophthalate with the generation of molecular nitrogen, and release blue light with a wavelength of 425nm when returning to the ground state. The principle of its synergistic reaction is shown in the attached. Figure 1 , and can refer to the literature (Development of a highly sensitive chemiluminescence enzyme immunoassay using enhanced luminol as substrate.)

[0042] The present invention provides a sensitive and stable chemiluminescent reagent for detecting horseradish peroxidase in a sample. The highlight of the present invention is that a new second enhancer is proposed and combined with the first enhancer reported before, so that the light emitted by the system is stabilized while ensuring that the sensitivity is not reduced too much. The proposed new second enhancer is DL-tryptophan or L-tryptophan, which can be extended to indole derivatives, such as 5-hydroxytryptamine, auxin, and indole-3-acetic acid.

[0043] On the basis of the above formula, glycerin, hyaluronic acid, propylene glycol, etc. are added to the reagent formula. The purpose is to utilize the greater density of the above substances compared to pure water, so in actual use it will increase the deep adhesion of the reagent to the surface of the solid phase carrier; at the same time, because it has the function of absorbing moisture and moisturizing, it can facilitate long-term testing without worrying about the problem of reagent volatilization.

[0044] The present invention uses a combination of phenothiazine compounds and indole derivatives, and according to the "ping-pong theory" described above, the two enhancers are combined to exert a synergistic effect, which not only improves the brightness, but also prolongs the luminescence time due to the mutual transfer of electrons. Further, the present invention can also add a moisturizer at the same time to ensure the stability of the reagent incubated on the peroxidase. At the same time, due to the increase in density, it can prevent the luminescence detection results from being inaccurate due to excessive residual liquid in the carrier, especially in the immunoblotting experiment, the improvement effect is most obvious. Therefore, the luminescent reagent can be applied to various enzyme-linked immunosorbent assays and immunoblotting experiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 It is the principle of synergistic reaction;

[0046] Figure 2These are the luminescence detection graphs in Example 3. The sample loading amounts in each graph are 100ug, 50ug, 25ug, 12.5ug, 6.25ug and 3.125ug from left to right. DETAILED DESCRIPTION

[0047] Unless otherwise specified, the test methods used in the following examples are conventional methods.

[0048] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0049] A highly sensitive and signal-stable chemiluminescent reagent of the present invention comprises reagent A solution and reagent B solution;

[0050] Recipe 1

[0051] Liquid A:

[0052] Luminol 5mM

[0053] Sodium 3-(10-phenothiazinyl)propane-1-sulfonate 10 mM

[0054] 5-HT 10mM

[0055] Tris 100mM

[0056] The pH was adjusted to between 8.5 and 8.8 using 6 M hydrochloric acid.

[0057] Liquid B:

[0058] Hydrogen peroxide 0.01 mM

[0059] EDTA 0.002mM

[0060] Glycerol 300mM

[0061] Hyaluronic acid 0.1mM

[0062] Acetic acid-sodium acetate buffer 50mM pH 5.0-5.5

[0063] Recipe 2

[0064] Liquid A:

[0065] Luminol 2mM

[0066] Sodium 3-(10-phenothiazinyl)propane-1-sulfonate 10 mM

[0067] Tryptophan 15mM

[0068] Tris 100mM

[0069] The pH was adjusted to between 8.5 and 8.8 using 6 M hydrochloric acid.

[0070] Liquid B:

[0071] Hydrogen peroxide 0.01 mM

[0072] EDTA 0.002mM

[0073] Glycerol 300mM

[0074] Sodium benzoate solution 50mM pH between 2-4

[0075] Recipe 3:

[0076] Liquid A:

[0077] Luminol 10mM

[0078] Sodium 3-(10-phenothiazinyl)propane-1-sulfonate 10 mM

[0079] Tryptophan 5mM

[0080] Indole-3-acetic acid 5mM

[0081] Tris 100mM

[0082] The pH was adjusted to between 8.5 and 8.8 using 6 M hydrochloric acid.

[0083] Liquid B:

[0084] Hydrogen peroxide 0.01 mM

[0085] EDTA 0.002mM

[0086] Propylene glycol 20mM

[0087] Sodium benzoate solution 50mM pH between 2-4

[0088] The above formulation is one representative one, and any of the listed compounds and corresponding concentration ranges can be combined into formulations.

[0089] Example 1

[0090] This example uses formula 1 to perform antigen-antibody detection.

[0091] This kit can be used for the detection of various in vitro antibody antigens. Antigens and antibodies are coated in white or black opaque polystyrene microplates, and then the content of antigens or antibodies is detected through the coupled HRP marker, taking the commonly used alpha-fetoprotein (AFP) as an example.

[0092] The reference substance was a commercially available alpha-fetoprotein quantitative detection kit (chemiluminescent immunoassay (Transgene), using the reagents used in the calibration substance for detecting and establishing a standard curve, coated in a white polystyrene microplate, with a concentration range of 0-500 ng / ml. It was incubated with the corresponding antibody coupled to HRP, and its luminescence intensity was detected using a BioTek Synergy H1 full-function microplate reader, and the microwells with a concentration of 250 ng / ml were selected to detect the luminescence value every 5 minutes. The measurement lasted for 2 hours.

[0093] Results Table 1 shows the concentration of alpha-fetoprotein (AFP) and the corresponding luminescence intensity.

[0094] Table 1 Alpha-fetoprotein (AFP) concentration and corresponding luminescence intensity

[0095] Calibrator concentration (ng / ml) Example Formula 1 Reference 0 749 1325 15.625 28346 29259 31.25 61263 51918 62.5 136642 106476 125 270878 241821 250 537853 538905 500 1352011 1015941

[0096] In the above luminescence results, the linear fitting correlation between protein concentration and luminescence value data of Example Formula 1 and the reference substance is greater than 0.95. However, the luminescence value of the same concentration is greater than the control, and the standard curve has a larger slope, indicating that the accuracy and sensitivity of the detection results of the formula of the present invention are higher.

[0097] Example 2

[0098] This embodiment uses formula 2 to compare the thermal stability of chemiluminescent reagents

[0099] The reagents were prepared according to formula 2 and placed at 37 degrees Celsius for 4, 8, and 12 days, and compared with the luminescent reagent prepared on the same day. The comparison experiment directly used horseradish peroxidase dissolved in physiological saline and diluted the horseradish peroxidase to a concentration of 1X10 -15 mol / L, take 100ul of each of the luminescent solution A and solution B that have been placed for different days, mix them and add them to the white polystyrene microplate, then add the diluted horseradish peroxidase to each well. Use the BioTek Synergy H1 full-function microplate reader to detect its luminescence value. The results are shown in Table 2.

[0100] Table 2 Thermal stability test of chemiluminescent reagents

[0101]

[0102] According to the above results, it can be seen that the luminescent reagent is stable and can be stored for a long time.

[0103] Example 3

[0104] Example: Using formula 3, applied to protein immunoblotting detection

[0105] The specific operation process is as follows:

[0106] Mouse liver tissue was selected, and protein was extracted using RIPA lysis buffer, and then the protein concentration was detected. According to the measured protein concentration, the protein mass added to each well of protein electrophoresis was calculated to be 100ug, 50ug, 25ug, 12.5ug, 6.25ug and 3.125ug respectively. Protein electrophoresis and membrane transfer were performed according to routine operations. The membrane used was NC membrane. The NC membrane was blocked with skimmed milk powder and incubated with Histone H3 primary antibody overnight, and then incubated with HRP-labeled secondary antibody, and then luminescent reagent was used for luminescence detection. The control product selected was an imported best-selling product: SuperSignal West Dura chemiluminescent substrate. To ensure consistent results, the same NC membrane was used during the test, and different luminescent solutions were used repeatedly for detection and comparison.

[0107] The results are as follows Figure 2 As shown, the exposure time is 30s, and the stability of the product of the present invention is slightly higher than that of the reference product.

[0108] It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above and that the present invention can be implemented in other specific forms without departing from the spirit or essential features of the present invention. Therefore, the embodiments should be considered exemplary and non-restrictive in all respects, and the scope of the present invention is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims be included in the present invention.

[0109] In addition, it should be understood that although the present specification is described according to implementation modes, not every implementation mode contains only one independent technical solution. This description of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation modes that can be understood by those skilled in the art.

Claims

1. A chemiluminescent kit, characterized in that: Including A liquid and B liquid, The A liquid component is: 1) Luminescent substrate: luminol 10mM; 2) The first enhancer: 10 mM sodium 3-(10-phenothiazinyl)propane-1-sulfonate; 3) Second enhancer: 5 mM each of tryptophan and indole-3-acetic acid; 4) Buffer A: Tris 100mM, adjust the pH to between 8.5-8.8 using 6M hydrochloric acid; The B liquid components are: 1) Hydrogen peroxide 0.01mM; 2) EDTA 0.002mM; 3) Propylene glycol 20mM; 4) Sodium benzoate solution 50mM, pH between 2-4.

2. Use of the chemiluminescent kit according to claim 1 in preparing a kit for immunoblotting experiments or enzyme-linked immunosorbent assays.